← Back to home

UNTREATED ADVANCED OR METASTATIC GASTRIC, GASTROESOPHAGEAL JUNCTION, OR ESOPHAGEAL ADENOCARCINOMA

Clinical trials for UNTREATED ADVANCED OR METASTATIC GASTRIC, GASTROESOPHAGEAL JUNCTION, OR ESOPHAGEAL ADENOCARCINOMA explained in plain language.

Never miss a new study

Get alerted when new UNTREATED ADVANCED OR METASTATIC GASTRIC, GASTROESOPHAGEAL JUNCTION, OR ESOPHAGEAL ADENOCARCINOMA trials appear

Sign up with your email to follow new studies for UNTREATED ADVANCED OR METASTATIC GASTRIC, GASTROESOPHAGEAL JUNCTION, OR ESOPHAGEAL ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1 Not yet recruiting 1

New stomach cancer drug challenges standard treatment in major trial

Disease control Recruiting now

This study is testing whether a new drug called pumitamig works better than the current standard drug nivolumab when both are given with chemotherapy. It's for people with advanced stomach or esophageal cancer who haven't had previous treatment. The trial will measure how well tu…

Matched conditions: UNTREATED ADVANCED OR METASTATIC GASTRIC, GASTROESOPHAGEAL JUNCTION, OR ESOPHAGEAL ADENOCARCINOMA

Phase: PHASE2, PHASE3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control

Last updated Apr 01, 2026 14:41 UTC

UNTREATED ADVANCED OR METASTATIC GASTRIC, GASTROESOPHAGEAL JUNCTION, OR ESOPHAGEAL ADENOCARCINOMA

Get alerted when new UNTREATED ADVANCED OR METASTATIC GASTRIC, GASTROESOPHAGEAL JUNCTION, OR ESOPHAGEAL ADENOCARCINOMA trials appear

New stomach cancer drug challenges standard treatment in major trial